Patents by Inventor Luisa Rusconi

Luisa Rusconi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of a kinase inhibitor for the treatment of particular resistant tumors
    Patent number: 8084455
    Abstract: The invention provides low molecular weight compounds, namely tetrahydropyrrolo[3,4-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, such as Imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compounds capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: December 27, 2011
    Assignee: Nerviano Medical Sciences S.r.l.
    Inventors: Daniele Fancelli, Antonella Isacchi, Michele Modugno, Juergen Moll, Luisa Rusconi, Chiara Soncini, Rosita Lupi
  • Use of a kinase inhibitor for the treatment of particular resistant tumors
    Patent number: 7803829
    Abstract: The invention provides low molecular weight compounds, namely 1H-thieno[2,3-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, such as Imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compounds capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: September 28, 2010
    Assignee: Nerviano Medical Sciences S.r.l.
    Inventors: Daniele Fancelli, Antonella Isacchi, Michele Modugno, Jurgen Moll, Luisa Rusconi, Chiara Soncini, Rosita Lupi
  • Use of a Kinase Inhibitor for the Treatment of Particular Resistant Tumors
    Publication number: 20100035876
    Abstract: The invention provides low molecular weight compounds, namely tetrahydropyrrolo[3,4-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, such as Imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compounds capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase.
    Type: Application
    Filed: March 29, 2007
    Publication date: February 11, 2010
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Daniele Fancelli, Antonella Isacchi, Michele Modugno, Juergen Moll, Luisa Rusconi, Chiara Soncini, Rosita Lupi
  • USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS
    Publication number: 20100022532
    Abstract: The invention provides low molecular weight compounds, namely 1H-thieno[2,3-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, such as Imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compounds capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase.
    Type: Application
    Filed: March 29, 2007
    Publication date: January 28, 2010
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Daniele Fancelli, Antonella Isacchi, Michele Modugno, Jurgen Moll, Luisa Rusconi, Chiara Soncini, Rosita Lupi